Sustained-release version of BPH drug deemed approvable

The FDA issued an approvable letter for a sustained-release formulation of doxazosin mesylate (Cardura XL), an alpha-blocker used to treat BPH.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria